|Petition Title||Replace naloxone co-prescription requirement with FDA-approved opioid-reversal agents|
|Date Filed||7/27/2022 [Transmittal Sheet]|
The petitioner requests that the Board amend 18VAC85-21-40 to replace the requirement to co-prescribe naloxone with certain medications or conditions with a requirement to co-prescribe an FDA-approved opioid-reversal agent.
The petition for rulemaking will be published in the Virginia Register of Regulations on August 29, 2022. The petition will also be published on the Virginia Regulatory Town Hall at www.townhall.virginia.gov to receive public comment, which will open on August 29, 2022 and will close on September 19, 2022. The Board will consider the petition and all comments in support or opposition at the next meeting after the close of public comment, currently scheduled for October 6, 2022.
|Comment Period||Ended 9/19/2022 2 comments|
|Agency Decision||Take no action [Transmittal Sheet]|
|Agency Decision Summary||
The Board considered the petition at its October 6, 2022 meeting and decided to take no action at this time. The Board intends to review the entire chapter devoted to opioid and buprenorphine prescribing following the issuance of new guidance by the Centers for Disease Control and Prevention. The Board will include this issue as a revision to be considered along with any other changes to Chapter 21.
|Name / Title:||William L. Harp, M.D. / Executive Director|
9960 Mayland Drive
|Telephone:||(804)367-4558 FAX: (804)527-4429 TDD: ()-|